15,257 stock options granted to Coya (NASDAQ: COYA) chair

Rhea-AI Filing Summary

Coya Therapeutics, Inc. reported that Executive Chairman Howard Berman received a stock option grant on 01/22/2026. The option gives him the right to buy 15,257 shares of common stock at an exercise price of $4.73 per share.

These options vest in monthly installments over the next 36 months, as long as he remains in continuous service through each vesting date. The filing also states that if there is a change in control of the company, all unvested shares under this option will vest and the option will become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended in November 2022.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Berman Howard

Role Executive Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,257	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,257 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berman Howard

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TX 77057

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.73	01/22/2026		A		15,257		(1)	01/22/2036	Common Stock, par value $0.0001 per share	15,257	$0	15,257	D

Explanation of Responses:

1. Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

	/s/ David Snyder, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did COYA report for Howard Berman?

COYA reported that Executive Chairman Howard Berman received a grant of stock options to buy 15,257 shares of common stock at an exercise price of $4.73 per share on 01/22/2026.

Is the Howard Berman transaction at Coya Therapeutics a purchase or a grant?

The filing shows an option grant, coded as transaction type A (acquired), giving Howard Berman stock options rather than reflecting an open-market share purchase or sale.

How do the granted COYA stock options vest for Howard Berman?

According to the footnote, the shares underlying the option vest in monthly installments over 36 months, subject to Howard Berman’s continuous service through each vesting date.

What happens to Howard Berman’s COYA options if there is a change in control?

If there is a change in control of Coya Therapeutics, all shares underlying this option will fully vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan.

How many COYA options does Howard Berman hold after this transaction?

After this grant, Howard Berman is reported as beneficially owning 15,257 stock options related to Coya Therapeutics common stock, all held as direct ownership.

Does Howard Berman pay anything for receiving these COYA stock options?

The filing lists a $0 price for the derivative security itself, indicating the options were granted at no upfront cost, with an exercise price of $4.73 per share if exercised.